Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study

RF Schlenk; P Paschka; J Krzykalla; D Weber; S Kapp-Schwoerer; VI Gaidzik; C Leis; W Fiedler; T Kindler; T Schroeder; K Mayer; M Lubbert; MA Wattad; KS Gotze; HA Horst; E Koller; G Wulf; J Schleicher; M Bentz; Richard Greil; B Hertenstein; J Krauter; U Martens; D Nachbaur; M Abu Samra; M Girschikofsky; A Benner; F Thol; M Heuser; A Ganser; K Dohner

doi:10.1182/blood-2018-99-113442

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study

RF Schlenk
, P Paschka
, J Krzykalla
, D Weber
, S Kapp-Schwoerer
, VI Gaidzik
, C Leis
, W Fiedler
, T Kindler
, T Schroeder
, K Mayer
, M Lubbert
, MA Wattad
, KS Gotze
, HA Horst
, E Koller
, G Wulf
, J Schleicher
, M Bentz
, Richard Greil

B Hertenstein, J Krauter, U Martens, D Nachbaur, M Abu Samra, M Girschikofsky, A Benner, F Thol, M Heuser, A Ganser, K Dohner

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

5 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	BLOOD
Jahrgang	132
DOIs	https://doi.org/10.1182/blood-2018-99-113442
Publikationsstatus	Veröffentlicht - 2018
Veranstaltung	60th Annual Meeting of the American-Society-of-Hematology (ASH) - San Diego, CA Dauer: 1 Dez. 2018 → 4 Dez. 2018

Zugriff auf Dokument

10.1182/blood-2018-99-113442

Dieses zitieren

Schlenk, RF., Paschka, P., Krzykalla, J., Weber, D., Kapp-Schwoerer, S., Gaidzik, VI., Leis, C., Fiedler, W., Kindler, T., Schroeder, T., Mayer, K., Lubbert, M., Wattad, MA., Gotze, KS., Horst, HA., Koller, E., Wulf, G., Schleicher, J., Bentz, M., ... Dohner, K. (2018). Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. BLOOD , 132. https://doi.org/10.1182/blood-2018-99-113442

Schlenk, RF ; Paschka, P ; Krzykalla, J et al. / Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. in: BLOOD 2018 ; Jahrgang 132.

@article{7586bef6e1494291bfcbfd89c79d6acc,

title = "Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study",

author = "RF Schlenk and P Paschka and J Krzykalla and D Weber and S Kapp-Schwoerer and VI Gaidzik and C Leis and W Fiedler and T Kindler and T Schroeder and K Mayer and M Lubbert and MA Wattad and KS Gotze and HA Horst and E Koller and G Wulf and J Schleicher and M Bentz and Richard Greil and B Hertenstein and J Krauter and U Martens and D Nachbaur and \{Abu Samra\}, M and M Girschikofsky and A Benner and F Thol and M Heuser and A Ganser and K Dohner",

year = "2018",

doi = "10.1182/blood-2018-99-113442",

language = "English",

volume = "132",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

note = "60th Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 01-12-2018 Through 04-12-2018",

}

Schlenk, RF, Paschka, P, Krzykalla, J, Weber, D, Kapp-Schwoerer, S, Gaidzik, VI, Leis, C, Fiedler, W, Kindler, T, Schroeder, T, Mayer, K, Lubbert, M, Wattad, MA, Gotze, KS, Horst, HA, Koller, E, Wulf, G, Schleicher, J, Bentz, M, Greil, R, Hertenstein, B, Krauter, J, Martens, U, Nachbaur, D, Abu Samra, M, Girschikofsky, M, Benner, A, Thol, F, Heuser, M, Ganser, A & Dohner, K 2018, 'Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study', BLOOD , Jg. 132. https://doi.org/10.1182/blood-2018-99-113442

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. / Schlenk, RF; Paschka, P; Krzykalla, J et al.
in: BLOOD , Jahrgang 132, 2018.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study

AU - Schlenk, RF

AU - Paschka, P

AU - Krzykalla, J

AU - Weber, D

AU - Kapp-Schwoerer, S

AU - Gaidzik, VI

AU - Leis, C

AU - Fiedler, W

AU - Kindler, T

AU - Schroeder, T

AU - Mayer, K

AU - Lubbert, M

AU - Wattad, MA

AU - Gotze, KS

AU - Horst, HA

AU - Koller, E

AU - Wulf, G

AU - Schleicher, J

AU - Bentz, M

AU - Greil, Richard

AU - Hertenstein, B

AU - Krauter, J

AU - Martens, U

AU - Nachbaur, D

AU - Abu Samra, M

AU - Girschikofsky, M

AU - Benner, A

AU - Thol, F

AU - Heuser, M

AU - Ganser, A

AU - Dohner, K

PY - 2018

Y1 - 2018

U2 - 10.1182/blood-2018-99-113442

DO - 10.1182/blood-2018-99-113442

M3 - Abstract (Journal)

SN - 0006-4971

VL - 132

JO - BLOOD

JF - BLOOD

T2 - 60th Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 1 December 2018 through 4 December 2018

ER -

Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI et al. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. BLOOD . 2018;132. doi: 10.1182/blood-2018-99-113442